Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives

Lidia Giraudo; Loretta Gammaitoni; Michela Cangemi; Ramona Rotolo; Massimo Aglietta; Dario Sangiolo

doi:10.2217/imt.15.61

Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives

Immunotherapy. 2015;7(9):999-1010. doi: 10.2217/imt.15.61. Epub 2015 Aug 27.

Authors

Lidia Giraudo^{1

2}, Loretta Gammaitoni², Michela Cangemi², Ramona Rotolo², Massimo Aglietta^{1

3}, Dario Sangiolo^{1

2}

Affiliations

¹ Department of Oncology, University of Torino, Turin, Italy.
² Laboratory of Medical Oncology, Experimental Cell Therapy, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Turin, Italy.
³ Division & Laboratory of Medical Oncology, Candiolo Cancer Institute FPO- IRCCS, Candiolo, Turin, Italy.

PMID: 26310715
DOI: 10.2217/imt.15.61

Abstract

Cytokine-induced killer (CIK) cells are ex vivo expanded T lymphocytes endowed with potent MHC-independent antitumor activity. CIK cells are emerging as promising therapeutic approach in the field of cancer adoptive immunotherapy, with biologic features favoring their transferability into clinical applications. Aim of this review is to present the biologic characteristic of CIK cells, discussing the main preclinical findings and initial clinical applications in the field of solid tumors.

Keywords: adoptive immunotherapy; cytokine-induced killer cells; solid tumors.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Clinical Trials as Topic
Cytokine-Induced Killer Cells / immunology*
Cytokine-Induced Killer Cells / transplantation
Disease Models, Animal
Humans
Immunotherapy, Adoptive*
NK Cell Lectin-Like Receptor Subfamily K / metabolism*
Neoplasms / immunology
Neoplasms / therapy*

Substances

KLRK1 protein, human
NK Cell Lectin-Like Receptor Subfamily K